Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CDMC 2018: Shifting gears in the management of diabetes and CVDTranslating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
- CDMC 2018: Shifting gears in the management of diabetes and CVDBenefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: The GLP1 landscape - refining our understanding
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Screening for Diabetes: When is it meaningful and how should it be performed